Desire Projects

MINDCURE Provides Update on Strategic Review

Retrieved on: 
Wednesday, March 16, 2022
Desire, Phrase, Time, Philippine House Special Committee on Flagship Programs and Projects, Committee, Desire Projects, News, Board of directors, Canadian Securities Exchange, Multimedia, COVID-19, Interim, Disclosure, Mental health, Board, Dragon (magazine), Company, Leadership, Research, CSE, OTCQX, Director, Maintenance, Marketing, FRA, Risk management, Financial adviser, Management, Online shopping, 3D printing, BC, Engineering

VANCOUVER, BC, March 16, 2022 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), announced today that a special committee of the Company's board of directors (the "Special Committee") has concluded the initial phases of its previously announced strategic review process (the "Strategic Review Process").

Key Points: 
  • VANCOUVER, BC, March 16, 2022 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), announced today that a special committee of the Company's board of directors (the "Special Committee") has concluded the initial phases of its previously announced strategic review process (the "Strategic Review Process").
  • Canaccord Genuity Corp. is acting as the Special Committee's financial advisor in connection with the Strategic Review Process.
  • "Though we continue the Strategic Review Process, we have identified no available strategic alternatives that would require further development and execution of MINDCURE's existing business plan.
  • Certain information regarding MINDCURE and its business presented in this news release may constitute "forward-looking information" within the meaning of applicable securities laws.

MINDCURE Provides Update on Studies and Clinical Trials

Retrieved on: 
Thursday, November 4, 2021
Desire, Good, OTCQX, Research, Technology, USD, LinkedIn, GLP, Good laboratory practice, Ketamine, Ethics, MDMA, IP, Twitter, Advertising, CSE, Psychotherapy, FDA, Desire Projects, Ibogaine, Single-frequency network, Sandstone, GMP, Social media, Plan, Marketing, Company, Instagram, Phrase, Mental health, COVID-19, Letter, Awareness, Multimedia, Program, News, Solution, Female, Good manufacturing practice, FRA, MVP, Pharmaceutical industry, Public relations, Risk management

MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022.

Key Points: 
  • MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022.
  • The material will initially be used for broad cardiac and neurologic screens, with the potential to conduct in-depth behavioral studies.
  • This program has been identified as MSYNTH-001, and the Company expects results from the first studies during the first quarter of 2022.
  • In addition to advancing the scale of its synthetic ibogaine program, MINDCURE continues to explore options for drug pipeline expansion.

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Retrieved on: 
Monday, September 27, 2021
Desire, Star Trek: Phase II, News, Post-traumatic stress disorder, Health minister, Trauma, Distress, Man, University, Instagram, Clinical Obstetrics and Gynecology, Desire Projects, Solution, Moses Austin, III, CSE, Professor, MDMA, LinkedIn, Adult, Manifest and latent functions and dysfunctions, Phrase, Twitter, FRA, CEO, Gynaecology, Company, MAPS, Woman, Female, Fear, Obstetrics, Mental health, Social behavior, COVID-19, Hypoactive sexual desire disorder, Psychiatry, Research, PTSD, Laboratory, Psychotherapy, Theology, HSDD, Department, Birth control, Pharmaceutical industry, Risk management

As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.

Key Points: 
  • As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.
  • "We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind.
  • "I'm very excited to lead our team and launch a clinical studyfor the treatment of female Hypoactive Sexual Desire Disorder," said Dr. Joel Raskin, Chief Medical Officer, MINDCURE.
  • This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder."